ABBV is trading above its 200‑day moving average with RSI near 58 and rising volume, indicating strength; the $10.9 B Apogee acquisition adds pipeline depth and is expected to be EPS‑accretive.

Investors are upbeat about ABBV’s dividend resilience despite the acquisition, and the broader healthcare sector rally is pulling the stock higher; short interest has fallen sharply.

The large cash outlay raises short‑term free‑cash‑flow risk and could pressure the dividend if integration stalls, but the long‑term growth prospects from its neuroscience and immunology pipelines remain solid.

Technical indicators show a bullish crossover (20‑day EMA above 50‑day EMA), expanding MACD histogram, and tightening Bollinger bands, suggesting an imminent breakout toward the average analyst target of $272.71.